Measuring quality in arthritis care: The arthritis foundation's quality indicator set for analgesics

被引：23
作者：
Saag, KG [1 ]
Olivieri, JJ
Patino, F
Mikuls, TR
Allison, JJ
MacLean, CH
机构：
[1] Univ Alabama Birmingham, Ctr Educ & Res Therapeut & Musculoskeletal Disord, Birmingham, AL 35294 USA
[2] Univ Nebraska, Med Ctr, Omaha, NE 68182 USA
[3] Omaha Vet Adm Med Ctr, Omaha, NE 68182 USA
[4] Calif State Univ Los Angeles, Los Angeles, CA USA
来源：
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2004年 / 51卷 / 03期
关键词：
NSAIDs; analgesics; quality indicators; patient safety;
D O I：
10.1002/art.20422
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Objective. To develop systematically validated quality indicators (QIs) addressing analgesic safety. Methods, A comprehensive literature review of existing quality measures, clinical guidelines, anti evidence supporting potential QIs concerning nonselective (traditional) nonsteroidal anti-inflammatory drugs (NSAIDs) and newer cyclooxygenase 2-selective NSAIDs was undertaken. An expert panel then validated or refuted potential indicators utilizing a proven methodology. Results. Eleven potential QIs were proposed. After panel review, 8 were judged to be valid; an additional 10 were proposed by the panel, of which 7 were rated as valid. Quality indicators focused upon informing patients about risk, NSAID choice and gastrointestinal prophylaxis, and side effect monitoring. Conclusion. The 15 validated indicators were combined, where appropriate, to yield 10 validated processes of care indicators for the safe use of NSAIDs. These indicators developed by literature review and finalized by our expert panel process can serve as a basis to compare the quality of analgesic use provided by health care providers and delivery systems.
引用
收藏
页码：337 / 349
页数：13
相关论文
共 91 条
[1]  
Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
[2]  
[Anonymous], 1996, Arthritis Rheum, V39, P713
[3]   UTILIZATION OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
BAUM, C ;
KENNEDY, DL ;
FORBES, MB .
ARTHRITIS AND RHEUMATISM, 1985, 28 (06) :686-692
[4]   Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial [J].
Bensen, WG ;
Fiechtner, JJ ;
McMillen, JI ;
Zhao, WW ;
Yu, SS ;
Woods, EM ;
Hubbard, RC ;
Isakson, PC ;
Verburg, KM ;
Geis, GS .
MAYO CLINIC PROCEEDINGS, 1999, 74 (11) :1095-1105
[5]  
Bérard A, 2000, J RHEUMATOL, V27, P1648
[6]   Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, PS ;
Homer, CJ ;
Johnson, MS ;
Klein, JD ;
Lieu, TA ;
Mulrow, CD ;
Orleans, CT ;
Peipert, JF ;
Pender, NJ ;
Siu, AL ;
Teutsch, SM ;
Westhoff, C ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (02) :157-160
[7]   THE IMPACT OF RESEARCH QUALITY AND STUDY DESIGN ON EPIDEMIOLOGIC ESTIMATES OF THE EFFECT OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON UPPER GASTROINTESTINAL-TRACT DISEASE [J].
BOLLINI, P ;
RODRIGUEZ, LAG ;
GUTTHANN, SP ;
WALKER, AM .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (06) :1289-1295
[8]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[9]  
BONKOVSKY HL, 1994, HEPATOLOGY, V19, P1141, DOI 10.1002/hep.1840190511
[10]  
Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735
12345678910